Ebronucimab (AK102) is a recombinant IgG1-??2 monoclonal antibody specifically designed to target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This antibody is produced in Chinese Hamster Ovary (CHO) DG44 cells, ensuring high fidelity and consistency in antibody structure and function. Ebronucimab binds to PCSK9, inhibiting its ability to interact with the low-density lipoprotein receptor (LDLR), thereby modulating cholesterol metabolism. This makes it a valuable tool for research in cardiovascular diseases, lipid metabolism, and therapeutic development.
Ebronucimab (AK102) is a recombinant IgG1-??2 monoclonal antibody specifically designed to target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This antibody is produced in Chinese Hamster Ovary (CHO) DG44 cells, ensuring high fidelity and consistency in antibody structure and function. Ebronucimab binds to PCSK9, inhibiting its ability to interact with the low-density lipoprotein receptor (LDLR), thereby modulating cholesterol metabolism. This makes it a valuable tool for research in cardiovascular diseases, lipid metabolism, and therapeutic development.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula: